MET exon 14 skipping mutation (METex14), an oncogenic driver in approximately 3–4% of NSCLCs [42, 43], and MET amplification, found in 20% of EGFR-TKI-resistant NSCLC patients [44, 45], are often detected and frequently studied in NSCLC. This evidence concerns the gene MET and non-small cell lung carcinoma.